JP2018515507A - アルツハイマー病の処置のための神経細胞ストア作動性カルシウム流入経路の活性化方法 - Google Patents

アルツハイマー病の処置のための神経細胞ストア作動性カルシウム流入経路の活性化方法 Download PDF

Info

Publication number
JP2018515507A
JP2018515507A JP2017558374A JP2017558374A JP2018515507A JP 2018515507 A JP2018515507 A JP 2018515507A JP 2017558374 A JP2017558374 A JP 2017558374A JP 2017558374 A JP2017558374 A JP 2017558374A JP 2018515507 A JP2018515507 A JP 2018515507A
Authority
JP
Japan
Prior art keywords
trpc6
orai2
compound
stim2
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017558374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515507A5 (https=
Inventor
イリヤ ベズプロズバニー
イリヤ ベズプロズバニー
フア チャン
フア チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2018515507A publication Critical patent/JP2018515507A/ja
Publication of JP2018515507A5 publication Critical patent/JP2018515507A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017558374A 2015-05-08 2016-05-04 アルツハイマー病の処置のための神経細胞ストア作動性カルシウム流入経路の活性化方法 Pending JP2018515507A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562159083P 2015-05-08 2015-05-08
US62/159,083 2015-05-08
PCT/US2016/030704 WO2016182812A1 (en) 2015-05-08 2016-05-04 Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2018515507A true JP2018515507A (ja) 2018-06-14
JP2018515507A5 JP2018515507A5 (https=) 2019-06-13

Family

ID=57248333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017558374A Pending JP2018515507A (ja) 2015-05-08 2016-05-04 アルツハイマー病の処置のための神経細胞ストア作動性カルシウム流入経路の活性化方法

Country Status (6)

Country Link
US (1) US20180147206A1 (https=)
JP (1) JP2018515507A (https=)
KR (1) KR20180004242A (https=)
CN (1) CN107835688A (https=)
HK (1) HK1250658A1 (https=)
WO (1) WO2016182812A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110759985B (zh) * 2018-07-27 2021-11-09 中国人民解放军军事科学院军事医学研究院 一种用于微波辐射致神经元钙信号调节的生物标志物Orai2蛋白
RU2676100C1 (ru) * 2018-10-05 2018-12-26 федеральное государственное автономное образовательное учреждение высшего образования "Санкт-Петербургский политехнический университет Петра Великого" (ФГАОУ ВО "СПбПУ") Применение производных пиперазина для лечения болезни Альцгеймера и деменций альцгеймеровского типа с нарушенной внутриклеточной кальциевой сигнализацией
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071477A1 (en) * 2009-11-30 2012-03-22 Senex Biotechnology, Inc. Cdki pathway inhibitors and uses thereof
JP2013500255A (ja) * 2009-07-21 2013-01-07 プレジデント アンド フェロウズ オブ ハーバード カレッジ 自食作用の強力な小分子阻害剤、およびそれの使用方法
US20140271668A1 (en) * 2013-03-15 2014-09-18 Georgetown University Increasing parkin activity by administering a deubiquitinating enzyme inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500255A (ja) * 2009-07-21 2013-01-07 プレジデント アンド フェロウズ オブ ハーバード カレッジ 自食作用の強力な小分子阻害剤、およびそれの使用方法
US20120071477A1 (en) * 2009-11-30 2012-03-22 Senex Biotechnology, Inc. Cdki pathway inhibitors and uses thereof
US20140271668A1 (en) * 2013-03-15 2014-09-18 Georgetown University Increasing parkin activity by administering a deubiquitinating enzyme inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
旭硝子財団 助成研究成果報告, JPN6020008554, 2014, pages 79 - 1, ISSN: 0004227259 *

Also Published As

Publication number Publication date
CN107835688A (zh) 2018-03-23
US20180147206A1 (en) 2018-05-31
HK1250658A1 (zh) 2019-01-11
WO2016182812A8 (en) 2017-03-09
WO2016182812A1 (en) 2016-11-17
KR20180004242A (ko) 2018-01-10

Similar Documents

Publication Publication Date Title
El Fatimy et al. MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways
Zhu et al. Beta-site amyloid precursor protein cleaving enzyme 1 inhibition impairs synaptic plasticity via seizure protein 6
Takata et al. Galantamine-induced amyloid-β clearance mediated via stimulation of microglial nicotinic acetylcholine receptors
Zhu et al. Loss of ARHGEF6 causes hair cell stereocilia deficits and hearing loss in mice
Vargas et al. WASP-1, a canonical Wnt signaling potentiator, rescues hippocampal synaptic impairments induced by Aβ oligomers
CN106030310A (zh) 可溶性高分子量（hmw）tau种类及其应用
JP6267160B2 (ja) アルツハイマー病等を含む神経疾患の１，２５ｄ３−ｍａｒｒｓが関与する治療薬及び治療法
JP2018515507A (ja) アルツハイマー病の処置のための神経細胞ストア作動性カルシウム流入経路の活性化方法
AU2017353446B2 (en) Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases
Jasmin et al. Differential regulation of ABCA1 and ABCG1 gene expressions in the remodeling mouse hippocampus after entorhinal cortex lesion and liver-X receptor agonist treatment
US10149836B2 (en) Isoxazole treatments for frontotemporal dementia
CA3113497A1 (en) Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
US20210330744A1 (en) Methods and Compositions for Treating Neurodegeneration and Fibrosis
EP2797591A1 (en) Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies
Tian et al. GALM Alleviates Aβ Pathology and Cognitive Deficit Through Increasing ADAM10 Maturation in a Mouse Model of Alzheimer’s Disease: N. Tian et al.: GALM improves AD
Lorke et al. α7-nicotinic acetylcholine receptors and β-amyloid peptides in Alzheimer’s disease
JP2000511901A (ja) 被験動物において長期記憶を増強するための方法、およびその使用
Pradhan Activation of translocator protein by XBD173 ameliorates cognitive deficits and neuropathology in an Alzheimer’s mouse model
KR20250010000A (ko) 신규 펩타이드 및 그의 용도
Wang et al. Pyrazole-derived TRPC3 antagonist ameliorates synaptic dysfunctions and memory deficits in Alzheimer’s disease models
Lawrence N-terminal beta amyloid fragments regulate nicotinic acetylcholine receptors
Gulisano A renewed vision for Amyloid beta and tau in Alzheimer s disease pathophysiology
Erdengiz Investigation of Alpha-Synuclein Induced Disruption of Calcium Homeostasis in Synucleinopathies
Small et al. Expression of Acetylcholinesterase in Alzheimer’s Disease Brain: Role in Neuritic Dystrophy and Synaptic Scaling
Dietrich Impact of N-Terminally Truncated Aβ4-42 on Memory and Synaptic Plasticity—Tg4-42 a New Mouse Model of Alzheimer’s Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201012